New project to shed light on neuropsychiatric disorder NEW YORK, NY (September 19, 2023) – The New York Genome Center (NYGC) is excited to announce it has received a 3-year grant of $4.5M from BD²: Breakthrough Discoveries for Thriving with Bipolar Disorder to support research aimed at better understanding the biological processes underlying bipolar disorder […]
New Center to Shine Light on the Dark Genome NEW YORK, NY (January 18, 2023) – The New York Genome Center (NYGC) announced the launch of the MacMillan Center for the Study of the Non-Coding Cancer Genome (MCSNCG) today, a major new initiative in cancer research to study the role and function of the non-coding […]
Expression of different forms of genes in human tissues has been mapped at unprecedented depth using emerging sequencing technology NEW YORK, NY (August 3, 2022) – Research on RNA diversity in human tissues, led by scientists from the New York Genome Center and the Broad Institute, is described in a recent study published in Nature. […]
Genome-wide approaches to engineer more effective anti-cancer immunotherapy NEW YORK, NY (March 16, 2022) – The first FDA-approved gene therapies are living drugs: immune cells taken from cancer patients engineered to target tumor cells. However, for many patients, these advanced therapies do not result in a long-lasting remission. Now, scientists at the New York Genome […]
NEW YORK, NY (August 10, 2020) – Cheryl A. Moore, President and Chief Operating Officer of the New York Genome Center (NYGC), has been named to the Crain’s New York Business list of 2020 Notable in Health Care. This is the second consecutive year that Ms. Moore has been recognized by Crain’s, having been selected […]
NEW YORK, NY (June 1, 2020) — A DNA-sequencing strategy powered by machine learning may pick up even very low levels of tumor DNA in blood samples, potentially enabling the early detection of cancer recurrence after surgery or other treatments, according to a study led by scientists at Weill Cornell Medicine and the New York […]
